COPD Foundation registers DELIVERY trial with Viatris, PARI, Theravance as collaborators
A phase 4 trial comparing nebulizer and handheld maintenance therapy in COPD patients is recruiting at two U.S. sites, sponsored by the COPD Foundation.
This week's update centers on a single newly registered trial involving Viatris as a collaborator.
- The "DELIVERY" study (NCT07816835) is a phase 4, randomized trial sponsored by the COPD Foundation, with Viatris Specialty LLC, PARI Respiratory Equipment, Inc., and Theravance Biopharma listed as collaborators.1 The trial is recruiting, with an actual start date of 2026-07-14 and an estimated primary completion in 2027-06.1 It plans to enroll 120 participants1 to test whether patients who report no symptomatic benefit from their maintenance handheld inhaler benefit from switching to nebulized therapy using comparable medication classes.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.